Key result
Empagliflozin gains FDA approval to reduce CV death or hospitalization in HFpEF regardless of diabetes.
Why the study?
Does empagliflozin reduce cardiovascular death or hospitalization in patients with heart failure with preserved left ventricular ejection fraction (>40%), with or without diabetes?
Does empagliflozin reduce cardiovascular death or hospitalization in patients with heart failure with preserved left ventricular ejection fraction (>40%), with or without diabetes?
Answers are grounded in this paper and cite their sources.
Empagliflozin has received FDA approval for the treatment of heart failure with preserved ejection fraction (>40%), expanding its indication.
Empagliflozin now has FDA approval for reducing cardiovascular death or hospitalization among patients with heart failure with preserved left ventricular ejection fraction, defined as more than 40%, with or without diabetes.
No takes yet. Share an insight, caveat, or question.
Howard Larkin (2022) studied this question. Empagliflozin received FDA approval to reduce cardiovascular death or hospitalization in patients with heart failure with preserved ejection fraction, with or without diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: